- Akebia press release (NASDAQ:AKBA): Q2 GAAP EPS of -$0.06 misses by $0.03.
- Revenue of $56.38M (-55.4% Y/Y) misses by $2.72M.
More on Akebia
- Akebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call Transcript
- Akebia: 'Hold' Through Regulatory And Financial Hurdles
- Akebia Therapeutics: Take Profits Before Second Quarter Report
- Akebia Therapeutics: Buy This Undervalued Stock At Just 77% Of Revenue
- Akebia Q2 2023 Earnings Preview
- Akebia plans to resubmit vadadustat NDA by end of Q3
- Akebia to resubmit FDA application for kidney drug by end of Q3
- Akebia settles last patent lawsuit related to kidney disease therapy
- Seeking Alpha’s Quant Rating on Akebia
- Earnings data for Akebia